Clomiphene Benefits: What Studies Report

Scope of this page

Clomiphene citrate is a small-molecule selective estrogen receptor modulator, not a peptide, but it appears frequently in discussions of hormone-axis pharmacology, so its evidence base is summarised here for context. This page organises published findings by outcome domain — what researchers measured, in whom, with what study design, and in which direction the result pointed. Nothing below is a claim that clomiphene will produce a given outcome in any individual. Where evidence for a commonly searched "benefit" is thin or absent in the literature cited here, that is stated plainly.

A 2019 review in Sexual Medicine Reviews described clomiphene citrate as acting at the hypothalamic–pituitary level to increase endogenous gonadotropin output, and discussed its off-label use in men with hypogonadism (PMID 30522888). A 2020 review of alternatives to testosterone replacement therapy in men with central hypogonadism similarly positioned clomiphene among agents studied for raising endogenous testosterone rather than supplying exogenous hormone (PMID 33375030).

Outcome domains at a glance

Ovulation induction in polycystic ovary syndrome

The largest single body of evidence concerns ovulation induction. A multicentre randomised trial published in The New England Journal of Medicine in 2014 compared letrozole with clomiphene for infertility in women with polycystic ovary syndrome and reported higher live-birth and ovulation rates with letrozole than with clomiphene (PMID 25006718). A 2023 systematic review and meta-analysis in Obstetrics and Gynecology pooled comparisons of letrozole and clomiphene citrate in PCOS and reported results favouring letrozole across fertility outcomes (PMID 36735392).

That comparative picture matters for how the word "benefit" is used. Clomiphene has long been studied as an ovulation-induction agent, and the trials above measured it as an active comparator rather than as an inert control — so the reported effects of clomiphene on ovulation were real measured effects, but the head-to-head direction in PCOS favoured letrozole in both the trial and the pooled analysis (PMID 25006718, PMID 36735392).

Protocol variations

A 2023 randomised controlled clinical trial published in Journal of Medicine and Life compared stair-step protocols for clomiphene citrate and letrozole in ovulation induction for women with PCOS, assessing both efficacy and safety of the two escalating-dose approaches (PMID 37520487). Protocol design is therefore one variable researchers have manipulated when studying clomiphene, alongside the choice of agent.

Predicting who responds

Not every participant ovulates on clomiphene, and one 2024 analysis in Fertility and Sterility examined antimüllerian hormone as a predictor, reporting that AMH level predicted ovulation in women with polycystic ovary syndrome treated with clomiphene and metformin (PMID 38154770). The study was an analysis of response prediction rather than a test of whether clomiphene itself works.

Clomiphene in combination and adjunct trials

A 2017 randomised clinical trial in JAMA evaluated acupuncture and clomiphene in Chinese women with polycystic ovary syndrome and reported that acupuncture did not increase live births, while clomiphene was the pharmacological arm against which that adjunct was tested (PMID 28655015). The trial is a useful illustration that clomiphene often appears in study designs as the established background therapy.

Unexplained infertility and other comparators

Outside PCOS, a 2019 contemporary meta-analysis in JOGC examined letrozole in unexplained infertility and included comparisons with clomiphene citrate, reporting pooled fertility outcomes across the available randomised evidence (PMID 30712904). A 2018 paper in the European Journal of Obstetrics, Gynecology, and Reproductive Biology compared tamoxifen with clomiphene citrate for ovulation induction in infertile women, placing clomiphene against another selective estrogen receptor modulator (PMID 29909264).

Male hypogonadism: hormonal outcomes

In men, the measured outcome in most studies is serum testosterone. A 2022 systematic review and meta-analysis in Andrology pooled studies of clomiphene citrate for men with hypogonadism and reported higher testosterone concentrations with clomiphene treatment, while also assessing safety data across the included studies (PMID 34933414). The 2019 Sexual Medicine Reviews article reached a similar descriptive conclusion, summarising clomiphene citrate as a treatment studied for hypogonadism with an emphasis on preserving endogenous production (PMID 30522888).

The 2020 review of alternatives to testosterone replacement therapy framed the practical rationale researchers have cited: exogenous testosterone suppresses the hypothalamic–pituitary–gonadal axis, whereas agents such as clomiphene were studied because they act upstream of the testis in men with central hypogonadism (PMID 33375030).

Enclomiphene versus clomiphene

Clomiphene citrate is a mixture of isomers, and a 2024 review in Translational Andrology and Urology examined the safety and efficacy of enclomiphene and clomiphene for hypogonadal men, comparing the isomer-specific preparation with the conventional mixture (PMID 39434750). Readers comparing the two compounds should note that the review assessed both efficacy and safety rather than efficacy alone (PMID 39434750).

Male infertility: semen parameters

A 2023 systematic review and meta-analysis in Andrology addressed clomiphene citrate for male infertility specifically, pooling studies that measured semen parameters and hormonal and pregnancy-related endpoints in men being treated for infertility (PMID 36680549). This is a different question from raising testosterone in symptomatic hypogonadism, and the two literatures — male infertility and male hypogonadism — were pooled separately in the respective 2023 and 2022 reviews (PMID 36680549, PMID 34933414).

Claimed benefits with little or no supporting evidence here

Several outcomes commonly attached to clomiphene in informal discussion are not endpoints in the studies summarised on this page:

• Muscle mass, strength or body composition. None of the reviews cited here — including the 2022 hypogonadism meta-analysis — were described as measuring lean mass or strength outcomes (PMID 34933414).
• Fat loss or metabolic endpoints. The PCOS trials and meta-analyses cited measured fertility outcomes such as ovulation and live birth, not weight or metabolic markers (PMID 25006718, PMID 36735392).
• Athletic performance or recovery. No study in this set evaluated performance endpoints; the male literature cited is confined to hypogonadism and infertility (PMID 36680549).
• Longevity, cognition or mood as primary endpoints. The 2019 review discussed clomiphene in the context of hypogonadism management rather than these outcomes (PMID 30522888).

Absence of evidence in this citation set is not evidence of absence — it simply means no finding can be attributed to a study here.

Adverse Events: What Studies Report

Safety was an explicit component of several analyses rather than an afterthought. The 2022 systematic review and meta-analysis of clomiphene citrate for men with hypogonadism evaluated safety alongside hormonal efficacy across the pooled studies (PMID 34933414), and the 2024 review of enclomiphene and clomiphene in hypogonadal men was framed around safety and efficacy together (PMID 39434750). On the female side, the 2023 randomised trial of stair-step clomiphene and letrozole protocols in PCOS compared safety as well as efficacy between the two agents (PMID 37520487). Event rates differ by population, dose schedule and duration, and no single pooled figure from these sources is reproduced here; the primary reports remain the appropriate source for specific tolerability data (PMID 34933414).

How to read the strength of this evidence

1. Design matters. The 2014 NEJM comparison was a randomised trial with live birth as the outcome, which is a stronger design for causal inference than observational data (PMID 25006718).
2. Comparator matters. Much of the clomiphene literature is active-comparator work against letrozole or tamoxifen, so "worse than letrozole" is not the same statement as "ineffective" (PMID 36735392, PMID 29909264).
3. Population matters. Findings in women with PCOS do not transfer to men with hypogonadism, and the two evidence bases were reviewed separately (PMID 34933414).
4. Heterogeneity matters. Pooled analyses in male infertility drew on studies with varying designs and endpoints, which the 2023 meta-analysis addressed in its synthesis (PMID 36680549).

Regulatory context

Clomiphene citrate is an approved prescription medicine for ovulation induction in several jurisdictions; its use in men is described in the literature as off-label, a point made explicitly in reviews of clomiphene for hypogonadism (PMID 30522888) and in reviews of alternatives to testosterone replacement therapy (PMID 33375030). Regulatory status varies by country and changes over time.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. For background on mechanism and terminology, see the overview at /learn/clomiphene/.

References

• Clomiphene citrate for male infertility: A systematic review and meta-analysis (Andrology, 2023)
• Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis (Andrology, 2022)
• Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (The New England Journal of Medicine, 2014)
• Letrozole Compared With Clomiphene Citrate for Polycystic Ovarian Syndrome: A Systematic Review and Meta-analysis (Obstetrics and Gynecology, 2023)
• Antimüllerian hormone level predicts ovulation in women with polycystic ovary syndrome treated with clomiphene and metformin (Fertility and Sterility, 2024)
• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial (JAMA, 2017)
• Clomiphene Citrate for the Treatment of Hypogonadism (Sexual Medicine Reviews, 2019)
• Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial (Journal of Medicine and Life, 2023)
• Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (International Journal of Molecular Sciences, 2020)
• Tamoxifen versus clomiphene citrate for ovulation induction in infertile women (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2018)
• Letrozole and Unexplained Infertility: A Contemporary Meta-analysis (JOGC, 2019)